Warning: The NCBI web site requires JavaScript to function. more...
AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5.
Bracho G, Zayas C, Wang L, Coppel R, Pérez O, Petrovsky N.
Malar J. 2009 Feb 27;8:35.
Related citations
Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.
Burns JM Jr, Flaherty PR, Nanavati P, Weidanz WP.
Infect Immun. 2004 Oct;72(10):5605-12.
New vaccines require potent adjuvants like AFPL1 and AFCo1.
Pérez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, Balboa J, Acevedo R, Zayas C, Gil D, Mora N, González D, Pérez R, González E, Barberá R, Fajardo EM, Sierra G, Solís RL, Campa C.
Scand J Immunol. 2007 Aug-Sep;66(2-3):271-7.
The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
de Silva HD, Saleh S, Kovacevic S, Wang L, Black CG, Plebanski M, Coppel RL.
Malar J. 2011 Sep 16;10:266.
Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q, Peng G, Bu L, Lin Y, Zhang L, Lustigmen S, Wang H.
Vaccine. 2007 Jul 9;25(28):5155-65. Epub 2007 May 21.
The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol.
Rainczuk A, Smooker PM, Kedzierski L, Black CG, Coppel RL, Spithill TW.
Vaccine. 2003 Jun 20;21(21-22):3030-42.
Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV, Biswas S, Pillai CR, Saxena RK.
Vaccine. 2008 Aug 18;26(35):4526-35. Epub 2008 Jun 30.
Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV.
J Immunol. 2010 Dec 15;185(12):7583-95. Epub 2010 Nov 22.
CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.
Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL.
Infect Immun. 2004 Feb;72(2):949-57.
Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
Campo JD, Zayas C, Romeu B, Acevedo R, González E, Bracho G, Cuello M, Cabrera O, Balboa J, Lastre M.
Methods. 2009 Dec;49(4):301-8. Epub 2009 May 4.
Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
Lynch MM, Cernetich-Ott A, Weidanz WP, Burns JM Jr.
Clin Vaccine Immunol. 2009 Mar;16(3):293-302. Epub 2008 Dec 30.
Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.
Goschnick MW, Black CG, Kedzierski L, Holder AA, Coppel RL.
Infect Immun. 2004 Oct;72(10):5840-9.
The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.
Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J.
Clin Vaccine Immunol. 2010 Nov;17(11):1687-94. Epub 2010 Sep 8. Erratum in: Clin Vaccine Immunol. 2011 Feb;18(2):353.
Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
Kedzierski L, Black CG, Stowers AW, Goschnick MW, Kaslow DC, Coppel RL.
Vaccine. 2001 Sep 14;19(32):4661-8.
Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T, Komesu A, Otsuki H, Sattabongkot J, Udomsangpetch R, Matsumoto Y, Tsuji N, Wu Y, Torii M, Tsuboi T.
Infect Immun. 2005 Nov;73(11):7375-80.
Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM.
Vaccine. 2010 Apr 1;28(16):2818-26. Epub 2010 Feb 17.
Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.
Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nussenzweig MC, Steinman RM, Seder RA.
Vaccine. 2010 Oct 21;28(45):7256-66. Epub 2010 Sep 21.
Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.
Joshi MB, Gam AA, Boykins RA, Kumar S, Sacci J, Hoffman SL, Nakhasi HL, Kenney RT.
Infect Immun. 2001 Aug;69(8):4884-90.
OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei.
Meraldi V, Audran R, Romero JF, Brossard V, Bauer J, López JA, Corradin G.
Vaccine. 2003 Jun 2;21(19-20):2485-91.
Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.
BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, Thomas A, Druilhe P.
Eur J Immunol. 1997 May;27(5):1242-53.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on